Decision-Making / Indications ~ Prophylactic Surgery
~ Genetics of Breast & Ovarian Cancer

List was last updated on Nov 25, 2019 @ 11:32 am.


    • Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    • Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.
    • Breast. 2019 Nov 6;49:81-86. doi: 10.1016/j.breast.2019.10.012. [Epub ahead of print]
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    • Krassuski L, Vennedey V, Stock S, Kautz-Freimuth S.
    • BMC Med Inform Decis Mak. 2019 Aug 1;19(1):154. doi: 10.1186/s12911-019-0872-2.
    • Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer.
    • Bercow AS, Eisenhauer EL.
    • J Surg Oncol. 2019 Jul 29. doi: 10.1002/jso.25645. [Epub ahead of print]
    • Review
    • Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    • Chang J, Seng S, Yoo J, Equivel P, Lum SS.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07595-2. [Epub ahead of print]
    • Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice?
    • Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C.
    • Psychooncology. 2019 Jul 1. doi: 10.1002/pon.5166. [Epub ahead of print]
    • Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome.
    • Modaffari P, Ponzone R, Ferrari A, Cipullo I, Liberale V, D'Alonzo M, Maggiorotto F, Biglia N.
    • J Clin Med. 2019 Mar 5;8(3). pii: E313. doi: 10.3390/jcm8030313.
    • Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    • Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K.
    • Eur J Health Econ. 2019 Feb 21. doi: 10.1007/s10198-019-01038-1. [Epub ahead of print]
    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
    • AlHilli MM, Al-Hilli Z.
    • J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19.
    • Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
    • Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.
    • Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.
    • False-positive screening events and worry influence decisions about surgery among high-risk women.
    • Andersen MR, Karlan BY, Drescher CW, Paley P, Hawley S, Palomares M, Daly MB, Urban N.
    • Health Psychol. 2019 Jan;38(1):43-52. doi: 10.1037/hea0000647. Epub 2018 Nov 15.
    • Black and Minority Ethnic women's decision-making for risk reduction strategies after BRCA testing: Use of context and knowledge.
    • Machirori M, Patch C, Metcalfe A.
    • Eur J Med Genet. 2018 Dec 12. pii: S1769-7212(18)30405-1. doi: 10.1016/j.ejmg.2018.12.006. [Epub ahead of print]
    • Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.
    • Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]
    • Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    • Theobald KA, Susswein LR, Marshall ML, Roberts ME, Mester JL, Speyer D, Williams RNW, Knapke SC, Solomon SR, Murphy PD, Klein RT, Hruska KS, Solomon BD.
    • Ann Surg Oncol. 2018 Nov;25(12):3556-3562. doi: 10.1245/s10434-018-6581-8. Epub 2018 Aug 30.
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • Cancer experience in families affects decision making.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 25.

    Press: How a Loved One’s Experience With Cancer Guides Breast Cancer Decisions. (U.S. News & World Report)

    • Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.
    • Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS.
    • J Natl Cancer Inst. 2018 Sep 1;110(9):985-993. doi: 10.1093/jnci/djy015.
    • Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
    • Puski A, Hovick S, Senter L, Toland AE4.
    • J Genet Couns. 2018 Sep;27(5):1291-1301. doi: 10.1007/s10897-018-0254-4. Epub 2018 Mar 29.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes.
    • Weiss A, Garber JE, King T.
    • JAMA Surg. 2018 Aug 29. doi: 10.1001/jamasurg.2018.2493. [Epub ahead of print]
    • Review
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
    • Casey MJ, Salzman TA.
    • Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.
    • Breast Cancer Genetics and Indications for Prophylactic Mastectomy.
    • Krontiras H, Farmer M, Whatley J.
    • Surg Clin North Am. 2018 Aug;98(4):677-685. doi: 10.1016/j.suc.2018.03.004. Epub 2018 May 30.
    • Review
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.
    • Li Y, Devlin JJ.
    • Value Health. 2018 Jul;21(7):893-894. doi: 10.1016/j.jval.2018.02.010. Epub 2018 Apr 5.
    • Letter

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Original Research:

    A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

    • Previvor: An Oncology Nurse's Story of Cancer Risk Reduction Through Genetic Testing.
    • Kelly J.
    • Clin J Oncol Nurs. 2018 Jun 1;22(3):247-248. doi: 10.1188/18.CJON.247-248.
    • Editorial / Commentary
    • BRCA Mutations in the Young, High-Risk Female Population: Genetic Testing, Management of Prophylactic Therapies, and Implications for Plastic Surgeons.
    • Salibian AA, Frey JD, Choi M, Karp NS.
    • Plast Reconstr Surg. 2018 Jun;141(6):1341-1350. doi: 10.1097/PRS.0000000000004363.
    • Risk management decisions in women with BRCA1 and BRCA2 mutations.
    • Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K.
    • Am J Surg. 2018 May;215(5):899-903. doi: 10.1016/j.amjsurg.2018.02.010. Epub 2018 Feb 13.
    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Experiencing the cancer of a loved one influences decision-making for breast cancer prevention.
    • Padamsee TJ, Muraveva A, Yee LD, Wills CE, Paskett ED.
    • J Health Psychol. 2017 Dec 1:1359105317746480. doi: 10.1177/1359105317746480. [Epub ahead of print]
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Psychosocial Outcome Studies.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Sexual Health Is Paramount in the Counseling of Women at Risk for Breast or Ovarian Cancer Undergoing Risk-Reducing Surgery.
    • Rullo JE, Pruthi S.
    • J Natl Compr Canc Netw. 2017 Nov 1;15(11):1297. doi: 10.6004/jnccn.2017.7016.
    • Commentary
    • Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
    • O'Quigley J.
    • Ann Epidemiol. 2017 Oct;27(10):672-676. doi: 10.1016/j.annepidem.2017.09.005. Epub 2017 Sep 20.
    • Review
    • Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    • Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.
    • [Entitlement to prophylactic treatment in cases of genetic predisposition for breast cancer : Interdisciplinary perspectives].
    • Meier F, Ried J, Harney A, Rhiem K, Neusser S, Neumann A, Wasem J, Schmutzler R, Huster S, Dabrock P.
    • Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Oct;60(10):1102-1108. doi: 10.1007/s00103-017-2608-8.
    • Review, [Article in German]
    • Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    • Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.
    • Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.
    • Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up.
    • Interrante MK, Segal H, Peshkin BN, Valdimarsdottir HB, Nusbaum R, Similuk M, DeMarco T, Hooker G, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Heinzmann J, Kinney AY, Schwartz MD.
    • JNCI Cancer Spectr. 2017 Sep;1(1):pkx002. doi: 10.1093/jncics/pkx002. Epub 2017 Sep 22.
    • Longitudinal cancer risk management trajectories of BRCA1/2 mutation-positive reproductive-age women.
    • Young JL, Werner-Lin A, Mueller R, Hoskins L, Epstein N, Greene MH.
    • J Psychosoc Oncol. 2017 Jul-Aug;35(4):393-408. doi: 10.1080/07347332.2017.1292574. Epub 2017 Feb 14.
    • Managing hereditary breast cancer risk in women with and without ovarian cancer.
    • Peters ML, Garber JE, Tung N.
    • Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.
    • Review
    • Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    • Johns D, Agarwal J, Anderson L, Ying J, Kohlmann W.
    • J Womens Health (Larchmt). 2017 Jun;26(6):702-706. doi: 10.1089/jwh.2016.5931. Epub 2016 Dec 6.
    • A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    • Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ.
    • Value Health. 2017 Apr;20(4):547-555. doi: 10.1016/j.jval.2017.01.006. Epub 2017 Feb 23.

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Letter:

    A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.

    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    • Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.
    • Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.
    • Decision making for breast cancer prevention among women at elevated risk.
    • Padamsee TJ, Wills CE, Yee LD, Paskett ED.
    • Breast Cancer Res. 2017 Mar 24;19(1):34. doi: 10.1186/s13058-017-0826-5.
    • Preparing young people for future decision-making about cancer risk in families affected or at risk from hereditary breast cancer: A qualitative interview study.
    • Rowland E, Plumridge G, Considine AM, Metcalfe A.
    • Eur J Oncol Nurs. 2016 Dec;25:9-15. doi: 10.1016/j.ejon.2016.08.006. Epub 2016 Sep 20.
    • Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
    • Myklebust M, Gjengedal E, Strømsvik N.
    • J Genet Couns. 2016 Dec;25(6):1198-1206. Epub 2016 Apr 19.
    • A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
    • Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.
    • Isr Med Assoc J. 2016 Sep;18(9):549-552.

    Editorial:

    Handling Individuals with High Cancer Risk: One Size Doesn't Fit All.

    • Women Need More Information to Cope With Aftermath of BRCA-Prompted Preventive Surgery.
    • Ellie Leick.
    • Oncology Nursing News. 2016 Aug 1
    • Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
    • Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K.
    • Am J Clin Oncol. 2016 Aug;39(4):363-7. doi: 10.1097/COC.0000000000000073.
    • Addressing inherited predisposition for breast cancer in transplant recipients.
    • Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL.
    • J Surg Oncol. 2016 May;113(6):605-8. doi: 10.1002/jso.24193. Epub 2016 Feb 10.
    • Case report, Review
    • Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
    • Vetter L, Keller M, Bruckner T, Golatta M, Eismann S, Evers C, Dikow N, Sohn C, Heil J, Schott S.
    • Breast Cancer Res Treat. 2016 Apr;156(2):289-99. doi: 10.1007/s10549-016-3748-5. Epub 2016 Mar 9.
    • Influence of Personal Exposure to the Cancer of a Loved One on the Breast Cancer Prevention Decisions of High Risk Women.
    • Padamsee TJ, Muraveva A, Wills C, Yee L, Paskett E.
    • Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):561. 40th Annual (2016) ASPO meeting. doi: 10.1158/1055-9965.EPI-16-0090.
    • Conference abstract
    • Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    • Lheureux S, Karakasis K, Harter P, Scott C, Bacon M, Bryce J, Le Fur N, Pujade-Lauraine E, Oza AM.
    • Gynecol Oncol. 2016 Jan;140(1):90-94. doi: 10.1016/j.ygyno.2015.10.010. Epub 2015 Oct 22.
    • "The BRCA Responder" on Genetic Testing, Family Histories, and Why Counseling Is Key.
    • Kelly Johnson.
    • Oncology Nursing News. 2015 Aug 31.
    • Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers.
    • Portnoy DB, Loud JT, Han PK, Mai PL, Greene MH.
    • Health Psychol. 2015 Jul;34(7):709-17. doi: 10.1037/hea0000156. Epub 2014 Sep 22.
    • Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.
    • Garcia C, Lyon L, Littell RD, Powell CB.
    • Genet Med. 2014 Dec;16(12):896-902. doi: 10.1038/gim.2014.48. Epub 2014 May 22.
    • Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history.
    • Kwong A, Chu AT, Wu CT, Tse DM.
    • Fam Cancer. 2014 Sep;13(3):423-30. doi: 10.1007/s10689-014-9706-7.
    • Characterizing biased cancer-related cognitive processing: Relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
    • Carpenter KM, Eisenberg S, Weltfreid S, Low CA, Beran T, Stanton AL.
    • Health Psychol. 2014 Sep;33(9):1003-11. doi: 10.1037/a0032737. Epub 2013 Jun 17.
    • The Genetic Testing Experience of BRCA-Positive Women: Deciding Between Surveillance and Surgery.
    • Hesse-Biber S.
    • Qual Health Res. 2014 Jun;24(6):773-789. Epub 2014 Apr 18.
    • The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
    • Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti M.
    • Clin Genet. 2014 Jan;85(1):7-15. doi: 10.1111/cge.12298. Epub 2013 Nov 5.
    • Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Kim-Sing C, Ghadirian P, Sun P, Narod S.
    • Clin Genet. 2014 Jan;85(1):21-30. doi: 10.1111/cge.12233. Epub 2013 Aug 26.
    • The importance of understanding the psychological meaning of Angelina Jolie's surgery.
    • Goin MK.
    • J Psychiatr Pract. 2014 Jan;20(1):61-2. doi: 10.1097/01.pra.0000442939.69198.0c.
    • [Genetical aspects of surgical treatment in patients with hereditary breast cancer].
    • Bit-Sava EM.
    • Vestn Khir Im I I Grek. 2014;173(5):27-30.
    • [Article in Russian]
    • Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
    • Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW.
    • Fam Cancer. 2013 Mar;12(1):65-73. doi: 10.1007/s10689-012-9577-8.
    • [Prophylactic surgery in common hereditary cancer syndromes].
    • Noguès C, Mouret-Fourme E.
    • Bull Acad Natl Med. 2012 Oct;196(7):1237-45.
    • Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
    • This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D.
    • Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)